CUV (CUV) News
Follow CUV (CUV) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 9 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Morgans cuts Clinuvel Pharmaceuticals target price by 23% to A$10.00
Morgans cut its target price for Clinuvel Pharmaceuticals by 23% to A$10.00 per share.
EQUITY | Aug 30, 2026, 11:43 PM UTC
L
Spotlight for Clinuvel Turning to Vitiligo Trial Readout — Market Talk
Spotlight for Clinuvel Turning to Vitiligo Trial Readout — Market Talk
EQUITY | Aug 30, 2026, 11:01 PM UTC
L
CUV price target cut by Jefferies to A$39.30
Jefferies cut CUV’s price target by 3.7% to A$39.30 per share.
EQUITY | Aug 30, 2026, 09:47 PM UTC
L
Canaccord Genuity cuts Clinuvel price target 66% to A$9.52
Canaccord Genuity cut its price target for Clinuvel Pharmaceuticals by 66% to A$9.52 per share, TradingView News reports.
EQUITY | Aug 27, 2026, 11:10 PM UTC
L
Canaccord Genuity downgrades Clinuvel Pharmaceuticals to Hold
Canaccord Genuity downgraded Clinuvel Pharmaceuticals to Hold from Buy.
EQUITY | Aug 27, 2026, 11:10 PM UTC
L
CUV cites 10-year profitability, plans Nasdaq listing
CUV says profitability has been sustained for 10 years and it plans a Nasdaq listing, while reporting R&D progress in vitiligo.
EQUITY | Aug 27, 2026, 11:03 AM UTC
L
CUV: 10th year of profit, strong cash, Nasdaq move, and major R&D catalysts in vitiligo and peptides
CUV: 10th year of profit, strong cash, Nasdaq move, and major R&D catalysts in vitiligo and peptides
EQUITY | Aug 27, 2026, 09:47 AM UTC
L
Clinuvel lays groundwork for U.S. expansion
TradingView News says a decade of profitability underpins Clinuvel’s U.S. expansion.
EQUITY | Aug 27, 2026, 05:47 AM UTC
L
CUV profit streak continues; cash reserves and stable dividend cited
TradingView News says CUV’s profit streak continues with robust cash reserves and a stable dividend supporting U.S. growth.
EQUITY | Aug 27, 2026, 02:47 AM UTC